Editorial: Drug transporters: Recent advances and therapeutic applications

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 3-7

  Franke, R M ^a   Sparreboom, A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DOCETAXEL; EZETIMIBE; FEXOFENADINE; PACLITAXEL; PROBENECID; ABC TRANSPORTER; DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG TRANSPORT; EDITORIAL; HUMAN; HYDROPHOBICITY; HYPERCHOLESTEROLEMIA; LIPID BILAYER; MEMBRANE TRANSPORT; MIGRATION; POPULATION; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; GENETICS; METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 72849130506     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.239     Document Type: Editorial

References (25)

1. Van Winkle, L.J. Biomembrane Transport (Academic Press, San Diego, 1999).
2. Saier, M.H. Jr. Tracing pathways of transport protein evolution. Mol. Microbiol. 48, 1145-1156 (2003).
3. Lotspeich, W.D. Kidney, water and electrolyte metabolism. Annu. Rev. Physiol. 20, 339-376 (1958).
4. Ueda, K., Cardarelli, C., Gottesman, M.M. & Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 84, 3004-3008 (1987).
5. Dobson, P.D. & Kell, D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov. 7, 205-220 (2008).
6. +-independent organic anion transporter. Proc. Natl. Acad. Sci. U. S. A. 91, 133-137 (1994). (Pubitemid 24018657)
7. Sweet, D.H., Wolff, N.A. & Pritchard, J.B. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272, 30088-30095 (1997).
8. Sekine, T., Watanabe, N., Hosoyamada, M., Kanai, Y. & Endou, H. Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272, 18526-18529 (1997).
9. Grundemann, D., Gorboulev, V., Gambaryan, S., Veyhl, M. & Koepsell, H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372, 549-552 (1994).
10. Hagenbuch, B. Drug uptake systems in liver and kidney: a historic perspective. Clin. Pharmacol. Ther. 87, 39-47 (2010).
11. Glaeser, H. et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370 (2007).
12. Filipski, K.K., Mathijssen, R.H., Mikkelsen, T.S., Schinkel, A.H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402 (2009).
13. Lacy, S.A., Hitchcock, M.J., Lee, W.A., Tellier, P. & Cundy, K.C. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44, 97-106 (1998).
14. Cundy, K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127-143 (1999).
15. Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133 (2010).
16. Schinkel, A.H. et al. Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
17. Marchi, N., Gonzalez-Martinez, J., Nguyen, M.-T., Granata, T. & Janigro, D. Transporters in drug-refractory epilepsy: clinical significance. Clin. Pharmacol. Ther. 87, 13-15 (2010).
18. Cascorbi, I. ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics? Clin. Pharmacol. Ther. 87, 15-18 (2010).
19. Huang, S.-M., Zhang, L. & Giacomini, K.M. The International Transporter Consortium (ITC): a collaborative group of scientists from academia, industry, and the FDA. Clin. Pharmacol. Ther. 87, 32-36 (2010).
20. Kroetz, D.L., Yee, S.W. & Giacomini, K.M. The Pharmacogenomics of Membrane Transporters Project: research at the interface of genomics and transporter pharmacology. Clin. Pharmacol. Ther. 87, 109-116 (2010).
21. Koolen, S.L.W., Beijnen, J.H. & Schellens, J.H.M. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin. Pharmacol. Ther. 87, 126-129 (2010).
22. Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519 (2009).
23. Komoroski, B. et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85, 520-526 (2009).
24. Betters, J.L. & Yu, L. Transporters as drug targets: discovery and development of NPC1L1 inhibitors. Clin. Pharmacol. Ther. 87, 117-121 (2010).
25. Landfear, S.M. Transporters for drug delivery and as drug targets in parasitic protozoa. Clin. Pharmacol. Ther. 87, 122-125 (2010).